19 Dec 2023

Appointment of Chief Business Officer

Investors | Therapeutics

13 Dec 2023

ALS-6000-101 Phase 1a Three-Weekly Dose Escalation Safety Study Data

Investors | Therapeutics

04 Dec 2023

Shareholder update to review AVA6000 Phase 1a data

Investors | Therapeutics

15 Nov 2023

Affimer^® biotherapeutics: The next generation of cancer therapies

Blogs | Therapeutics

05 Oct 2023

Avacta to present promising new data from Affimer^® and pre|CISION^TM platform assets at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Investors | Therapeutics

20 Sep 2023

Appointment of Dr. Christina Coughlin as a consultant

Investors | Therapeutics

19 Sep 2023

Successful Completion of ALS-6000-101 Sixth Dose Escalation and Clinical Update

Investors | Therapeutics

21 Jun 2023

Successful Completion of Fifth Dose Escalation in AVA6000 Phase 1 Clinical Study

Investors | Therapeutics

05 Jun 2023

Avacta Achieves Second Milestone in AffyXell Joint Venture Triggering Increased Equity Stake

Investors | Therapeutics

27 Apr 2023

First Patient Dosed in the US in Avacta’s AVA6000 Phase 1 Clinical Study

Investors | Therapeutics